AKBX27922

AKBX27922 is an investigational **small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor** developed by **Akebia Therapeutics**. Preclinical data presented by Akebia describe it as a novel inhibitor of **prolyl-4-hydroxylase domain enzymes**, with reported activity against **PHD1** and **PHD2**, resulting in **HIF1alpha stabilization** and induction of HIF-responsive genes involved in erythropoiesis, angiogenesis, glycolysis, and cell survival. In cellular models, the compound was reported to shift metabolism from mitochondrial oxidative phosphorylation toward glycolysis, consistent with pharmacologic hypoxia signaling. It appears to be an early-stage research asset rather than an approved medicine, and publicly available information does not establish a clinical development program, commercial brand name, dosage form, or route of administration.